Will the next generation of basal insulins offer clinical advantages?

Diabetes, Obesity and Metabolism

Volumn 16, Issue 6, 2014, Pages 483-491

  Garber, A J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Basal insulin; Diabetes; Insulin degludec; Pegylated insulin lispro; U300 glargine

Indexed keywords

HEMOGLOBIN A1C; INSULIN DEGLUDEC; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN PEGLISPRO; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; GLARGINE; INSULIN; INSULIN LISPRO; INSULIN, POLYETHYLENE GLYCOL(B1)-; LONG ACTING INSULIN; MACROGOL DERIVATIVE;

CLINICAL ASSESSMENT; DIABETES MELLITUS; DIABETIC PATIENT; DRUG FORMULATION; DRUG INDICATION; DRUG METABOLISM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; DIABETES MELLITUS, TYPE 1;

DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN LISPRO; INSULIN, LONG-ACTING; POLYETHYLENE GLYCOLS;

EID: 84899657736     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12219     Document Type: Review

References (56)

1. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
2. Vaag A, Lund SS. Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. Eur J Endocrinol 2012; 166: 159-170.
3. Chan JC, Gagliardino JJ, Baik SH et al. Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS). Diabetes Care 2009; 32: 227-233.
4. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care 2008; 31: 81-86.
5. Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 2002; 45: S23-S28.
6. Lopez Stewart G, Tambascia M, Rosas Guzman J et al. Control of type 2 diabetes mellitus among general practitioners in private practice in nine countries of Latin America. Rev Panam Salud Publica 2007; 22: 12-20.
7. Frier BM. How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res Rev 2008; 24: 87-92.
8. Leiter LA, Yale JF, Chiasson JL, Harris SB, Kleinstiver P, Sauriol L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemic management. Can J Diabetes 2005; 29: 186-192.
9. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011; 14: 665-671.
10. Brod M, Christensen T, Bushnell DM. Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-country survey. J Med Econ 2012; 15: 77-86.
11. Jones TW, Porter P, Sherwin RS et al. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med 1998; 338: 1657-1662.
12. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 2012; 29: 682-689.
13. DeVries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev 2007; 23: 441-454.
14. Blonde L, Merilainen M, Karwe V, Raskin P. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study. Diabetes Obes Metab 2009; 11: 623-631.
15. Meneghini L, Liebl A, Abrahamson MJ. Insulin detemir: a historical perspective on a modern basal insulin analogue. Prim Care Diabetes 2010; 4(Suppl. 1): S31-S42.
16. Riddle MC. The treat-to-target trial and related studies. Endocr Pract 2006; 12(Suppl. 1): 71-79.
17. Riddle MC, Vlajnic A, Zhou R, Rosenstock J. Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies. Diabetes Obes Metab 2013; 15: 819-825.
18. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007; 9: 648-659.
19. Porcellati F, Bolli GB, Fanelli CG. Pharmacokinetics and pharmacodynamics of basal insulins. Diabetes Technol Ther 2011; 13(Suppl. 1): S15-S24.
20. Porcellati F, Rossetti P, Ricci NB et al. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1week of use compared with its first administration in subjects with type 1 diabetes. Diabetes Care 2007; 30: 1261-1263.
21. Heise T, Nosek L, Ronn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53: 1614-1620.
22. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007; 9: 290-299.
23. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
24. Luzio S, Dunseath G, Peter R, Pauvaday V, Owens DR. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Diabetologia 2006; 49: 1163-1168.
25. Plank J, Bodenlenz M, Sinner F et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005; 28: 1107-1112.
26. Porcellati F, Rossetti P, Busciantella NR et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 2007; 30: 2447-2452.
27. Home P, Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother 2006; 7: 325-343.
28. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012; 29: 2104-2114.
29. Nishimura E, Sorensen AR, Hansen BF et al. Insulin degludec, a new generation ultra-long acting basal insulin designed to maintain full metabolic effect while minimising mitogenic potential. Diabetologia 2010; 53(Suppl. 1): S388-S389.
30. Niskanen L, Leiter LA, Franek E et al. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur J Endocrinol 2012; 167: 287-294.
31. Heise T, Hövelmann U, Nosek L, Bøttcher SG, Granhall C, Haahr H. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetes 2011; 60(Suppl. 1A): LB11.
32. Heise T, Nosek L, Coester H-V et al. Steady state is reached within two to three days of once-daily administration of ultra-long-acting insulin degludec. Diabetes 2012; 61(Suppl. 1): A259.
33. Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012; 14: 944-950.
34. Kurtzhals P, Heise T, Strauss HM et al. Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec. Diabetes 2011; 60(Suppl. 1A): LB12.
35. Arold G, Kupcova V, Thrane M, Højbjerre M, Haahr HL. Insulin degludec has similar pharmacokinetic properties in subjects with hepatic impairment when compared to subjects with normal hepatic function. Diabetes 2012; 61(Suppl. 1): A289.
36. Kiss I, Arold G, Bøttcher SG, Thrane M, Haahr HL. Insulin degludec has similar pharmacokinetic properties in subjects with renal impairment and subjects with normal renal function. Diabetes 2012; 61(Suppl. 1): A296-A297.
37. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012; 14: 859-864.
38. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J Obes Relat Metab Disord 2004; 28(Suppl. 2): S23-S28.
39. Heller S, Buse J, Fisher M et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1489-1497.
40. Mathieu C, Hollander P, Miranda-Palma B et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): A 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013; 98: 1154-1162.
41. Garber AJ, King AB, Del Prato S et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1498-1507.
42. Onishi Y, Iwamoto K, Yoo SJ, Clauson P, Tamer SC, Park SW. Insulin degludec compared with insulin glargine in insulin-na€ýve patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Invest 2013; 15: 826-832.
43. Zinman B, Philis-Tsimikas A, Cariou B et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012; 35: 2464-2471.
44. Ratner R, Gough SC, Mathieu C et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013; 15: 175-184.
45. Meneghini L, Atkin SL, Gough SCL et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in people with type 2 diabetes. Diabetes Care 2013; 36: 858-864.
46. Hansen RJ, Cutler GB, Vick A et al. LY2605541: leveraging hydrodynamic size to develop a novel basal insulin. Diabetes 2012; 61: A228.
47. Owens RA, Lockwood JF, Dunbar JD et al. In vitro characterization of novel basal insulin LY2605541: reduced mitogenicity and IGF-IR binding. Diabetes 2012; 61(Suppl. 1): A425.
48. Heise T, Howey DC, Sinha VP et al. Steady-state pharmacokinetics (PK) and glucodynamics (GD) of the novel, long-acting basal insulin LY2605541 dosed once-daily (QD) in patients with type 2 diabetes mellitus (T2DM). Diabetes 2012; 61(Suppl. 1): A256.
49. Sinha VP, Howey DC, Soon DKW et al. Single-dose pharmacokinetics (PK) and glucodynamics (GD) of the novel, long-acting basal insulin LY2605541 in healthy subjects. Diabetes 2012; 61(Suppl.1): A273.
50. Linnebjerg H, Choi SL, Lam EQC, Mace KF, Hodgson TS, Sinha VP. Pharmacokinetics (PK) of the novel, long-acting basal insulin LY2605541 in subjects with varying degrees of renal function. Diabetes 2012; 61(Suppl. 1): A296.
51. Moore M, Smith MS, Mace KF et al. Novel pegylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes 2012; 61(Suppl. 1): A417.
52. Rosenstock J, Berghold A, Blevins T et al. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in patients with type 1 diabetes. Diabetes 2012; 61(Suppl.1): A263.
53. Bergenstal R, Rosenstock J, Arakaki RF et al. Reduced nocturnal hypoglycemia and weight loss with novel long-acting basal insulin LY2605541 compared with insulin glargine in patients with type 2 diabetes. Diabetes 2012; 61(Suppl. 1): A90.
54. Bastyr EJ, Bergenstal RM, Rosenstock J, Prince MJ, Qu Y, Jacober SJ. The novel long-acting insulin LY2605541 is superior to insulin glargine in lowering intra-day glucose variability and hypoglycemia event rate from continuous glucose monitoring (CGM) in patients with type 2 diabetes. Diabetes 2012; 61(Suppl. 1): A90.
55. Heise T, Nosek L, Hövelmann U, Bottcher SG, Hastrup H, Haahr H. Insulin degludec 200 U/ml is ultra-long-acting and has a flat and stable glucose lowering effect. Diabetes 2012; 61(Suppl. 1): A91.
56. Korsatko S, Deller S, Koehler G et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clin Drug Investig 2013; 33: 515-521.